CD2665
Selleck Chemicals
SKU:E6407-5MG
Couldn't load pickup availability

CD2665 is an antagonist of Retinoid Receptors used in studies of nuclear-receptor signaling. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to ligand-dependent transcriptional control and receptor co-regulation in developmental biology and endocrinology models.
By blocking Retinoid Receptors, CD2665 can be used to examine ligand-dependent transcriptional control and receptor co-regulation. This target class is commonly examined through reporter-gene, receptor-binding, and transcriptional assays, together with downstream-response mapping. In developmental biology and endocrinology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Target-focused assays involving Retinoid Receptors
- Receptor-blockade and ligand-competition studies
- Reporter-gene, receptor-binding, and transcriptional assays
- Phenotypic profiling in developmental biology and endocrinology models
Overall, CD2665 is appropriate when a defined chemical perturbant is needed to connect Retinoid Receptors with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in developmental biology and endocrinology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Targets:
- Retinoid Receptors
- Target Class:
- Nuclear Receptor
- Research Area:
- Developmental Biology • Endocrinology
- CAS No.:
- 170355-78-9
- Molecular Weight:
- 486.60
- Formula:
- C₃₁H₃₄O₅
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.